Vaccines | |
SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine | |
Jocelyn Ollier1  Thierry Guillaume1  Marie C. Béné1  Patrice Chevallier1  Audrey Grain1  Béatrice Clémenceau1  Henri Vié1  Maxime Jullien2  Pierre Peterlin2  Alice Garnier2  Amandine Le Bourgeois2  Marianne Coste-Burel3  | |
[1] CHU Nantes, CRCINA, INSERM, CNRS, Université de Nantes, F-44000 Nantes, France;Hematology Department, Nantes University Hospital, Nantes University, F-44000 Nantes, France;Virology Department, Nantes University Hospital, Nantes University, F-44000 Nantes, France; | |
关键词: COVID 19; vaccine; BNT162b2; SARS-CoV-2 mRNA; allogeneic hematopoietic stem cell transplantation; cellular immunity; | |
DOI : 10.3390/vaccines10030448 | |
来源: DOAJ |
【 摘 要 】
Background: At variance to humoral responses, cellular immunity after anti-SARS-CoV-2 vaccines has been poorly explored in recipients of allogeneic hematopoietic stem-cell transplantation (Allo-HSCT), especially within the first post-transplant years where immunosuppression is more profound and harmful. Methods: SARS-CoV-2 Spike protein-specific T-cell responses were explored after two doses of BNT162b2 mRNA vaccine in 45 Allo-HSCT recipients with a median time from transplant of less than 2 years by using INF-γ ELISPOT assay and flow-cytometry enumeration of CD4+ and CD8+ T lymphocytes with intracellular cytokine production of IFN-γ and TNF-α. Results: A strong TNF-α+ response from SARS-CoV-2-specific CD4+ T-cells was detected in a majority of humoral responders (89%) as well as in a consistent population of non-humoral responders (40%). Conclusions: T-cells are likely to participate in protection against COVID-19 viral infection, even in the absence of detectable antibody response, especially in the first years post-transplant in Allo-HSCT recipients.
【 授权许可】
Unknown